These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1725942)

  • 41. Benign prostatic hyperplasia--review of treatment options.
    Oehlke KJ; Branaugh ML
    S D Med; 2009 May; 62(5):202-3. PubMed ID: 19489345
    [No Abstract]   [Full Text] [Related]  

  • 42. [Medical therapy of benign prostatic hyperplasia].
    Altarac S
    Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological management of benign prostatic hyperplasia.
    Samkange C; Bhagat K
    Cent Afr J Med; 2000 Aug; 46(8):224-8. PubMed ID: 11317596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of finasteride in men with benign prostatic hyperplasia.
    Walsh PC
    J Urol; 1993 Apr; 149(4):932-3. PubMed ID: 7681121
    [No Abstract]   [Full Text] [Related]  

  • 46. Benign prostatic hyperplasia. Current strategy and pharmacotherapeutical potential.
    Dutkiewicz S
    Mater Med Pol; 1995; 27(1):3-6. PubMed ID: 8569274
    [No Abstract]   [Full Text] [Related]  

  • 47. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
    Vermeulen A; Giagulli VA; De Schepper P; Buntinx A
    Eur Urol; 1991; 20 Suppl 1():82-6. PubMed ID: 1722168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment and pharmacologic management of BPH in the context of common comorbidities.
    O'Leary MP
    Am J Manag Care; 2006 Apr; 12(5 Suppl):S129-40. PubMed ID: 16613527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
    Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
    MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
    [No Abstract]   [Full Text] [Related]  

  • 50. Role of 5 alpha-reductase inhibitors in the treatment of advanced prostatic carcinoma.
    Gormley GJ
    Urol Clin North Am; 1991 Feb; 18(1):93-8. PubMed ID: 1846988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked].
    MMW Fortschr Med; 2003 Jul; 145(27-28):58-9. PubMed ID: 14587193
    [No Abstract]   [Full Text] [Related]  

  • 52. [Hormonal therapy of benign prostatic hyperplasia].
    Horninger W; Bartsch G
    Urologe A; 1995 Jan; 34(1):9-15. PubMed ID: 7533450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological options in the treatment of benign prostatic hyperplasia.
    Kenny B; Ballard S; Blagg J; Fox D
    J Med Chem; 1997 Apr; 40(9):1293-315. PubMed ID: 9135028
    [No Abstract]   [Full Text] [Related]  

  • 54. Maximal androgen blockade in prostatic cancer.
    Denis L
    Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
    [No Abstract]   [Full Text] [Related]  

  • 55. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Non surgical treatment of benign prostatic hypertrophy. Past, present and future].
    Rossetti R
    J Urol (Paris); 1993; 99(6):367-8. PubMed ID: 7516394
    [No Abstract]   [Full Text] [Related]  

  • 57. [Non-surgical treatment of benign prostatic hypertrophy].
    Martini E; Vaggi L; Rucci A; Di Clemente L
    J Chir (Paris); 1994 Oct; 131(10):445-9. PubMed ID: 7532181
    [No Abstract]   [Full Text] [Related]  

  • 58. New medication for the treatment of benign prostatic hyperplasia.
    Miller CA
    Geriatr Nurs; 1993; 14(2):111-2. PubMed ID: 7681420
    [No Abstract]   [Full Text] [Related]  

  • 59. [Cost-effectiveness aspects of benign prostatic hyperplasia (BPH) therapy].
    Lopatkin NA; Ziborova IV; Sivkov AV; Apolikhin OI
    Urol Nefrol (Mosk); 1999; (1):22-6. PubMed ID: 11149340
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.